SAN DIEGO, CA, USA I February 2, 2015 I Lpath, Inc. (NASDAQ: LPTN), a leader in the discovery and development of lipid-targeted therapeutics, announced that it has submitted an Investigational New Drug (IND) application to the United States Food and Drug Administration (FDA) to conduct a Phase 1 study of Lpathomab™ for the treatment of neuropathic pain. The primary objective of the study is to evaluate the safety and tolerability of Lpathomab in subjects that are experiencing neuropathic pain. Lpath plans to begin enrolling patients once the FDA’s IND review period is complete and the study has been approved by the trial sites’ investigational review boards.
Lpathomab is an internally discovered, first-in-class antibody targeting Lysophosphatidic Acid, or LPA, a bioactive lipid that has been characterized in the scientific literature as playing a key role in nerve injury and neuropathic pain. Lpath’s preclinical studies showed strong in vivo results with Lpathomab in several different pain models, which suggest that LPA may be an attractive target across a variety of chronic pain conditions, including diabetic peripheral neuropathy, post-herpetic neuralgia, chemotherapy-induced neuropathic pain and pain associated with lumbosacral radiculopathy.
“We’ve made great progress in advancing Lpathomab towards the clinic and are eager to start our first-in-human study for our third antibody product candidate produced using our ImmuneY2TM drug discovery engine,” said Dario Paggiarino, M.D., chief development officer of Lpath. “We believe our approach of targeting the ligand (LPA) with an antibody may have distinct mechanistic advantages over traditional small molecule approaches to address an area of significant unmet medical need.”
About Lpath
San Diego-based Lpath, Inc. (NASDAQ: LPTN) is the category leader in lipid-targeted therapeutics. The company’s ImmuneY2™ drug-discovery engine has the unique ability to generate therapeutic antibodies that bind to and inhibit lipids that contribute to disease. The company has developed four drug candidates, two of which—iSONEP for wet AMD and ASONEP for cancer—are currently being investigated in Phase 2 trials. The other candidates are an anti-LPA antibody, Lpathomab, for neuropathic pain and an anti-leukotriene antibody, Altepan, which is being studied in models of inflammatory bowel disease, respiratory disease and inflammation. For more information, visit www.Lpath.com.
SOURCE: Lpath
Post Views: 95
SAN DIEGO, CA, USA I February 2, 2015 I Lpath, Inc. (NASDAQ: LPTN), a leader in the discovery and development of lipid-targeted therapeutics, announced that it has submitted an Investigational New Drug (IND) application to the United States Food and Drug Administration (FDA) to conduct a Phase 1 study of Lpathomab™ for the treatment of neuropathic pain. The primary objective of the study is to evaluate the safety and tolerability of Lpathomab in subjects that are experiencing neuropathic pain. Lpath plans to begin enrolling patients once the FDA’s IND review period is complete and the study has been approved by the trial sites’ investigational review boards.
Lpathomab is an internally discovered, first-in-class antibody targeting Lysophosphatidic Acid, or LPA, a bioactive lipid that has been characterized in the scientific literature as playing a key role in nerve injury and neuropathic pain. Lpath’s preclinical studies showed strong in vivo results with Lpathomab in several different pain models, which suggest that LPA may be an attractive target across a variety of chronic pain conditions, including diabetic peripheral neuropathy, post-herpetic neuralgia, chemotherapy-induced neuropathic pain and pain associated with lumbosacral radiculopathy.
“We’ve made great progress in advancing Lpathomab towards the clinic and are eager to start our first-in-human study for our third antibody product candidate produced using our ImmuneY2TM drug discovery engine,” said Dario Paggiarino, M.D., chief development officer of Lpath. “We believe our approach of targeting the ligand (LPA) with an antibody may have distinct mechanistic advantages over traditional small molecule approaches to address an area of significant unmet medical need.”
About Lpath
San Diego-based Lpath, Inc. (NASDAQ: LPTN) is the category leader in lipid-targeted therapeutics. The company’s ImmuneY2™ drug-discovery engine has the unique ability to generate therapeutic antibodies that bind to and inhibit lipids that contribute to disease. The company has developed four drug candidates, two of which—iSONEP for wet AMD and ASONEP for cancer—are currently being investigated in Phase 2 trials. The other candidates are an anti-LPA antibody, Lpathomab, for neuropathic pain and an anti-leukotriene antibody, Altepan, which is being studied in models of inflammatory bowel disease, respiratory disease and inflammation. For more information, visit www.Lpath.com.
SOURCE: Lpath
Post Views: 95
